Europe Cancer Biomarkers Market

Europe Cancer Biomarkers Market by Disease (Prostate Cancer, Breast Cancer, Lung Cancer, Colorectal Cancer, Cervical Cancer, and Others), Type (Protein Biomarkers, Genetic Biomarkers, and Others), Profiling Technology (OMICS Technology, Immunoassays, and Cytogenetics) - Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

  • Report ID: HC-1997
  • Author: Growth Market Reports
  • Rating: 4.9
  • Total Reviews: 3
  • No. Of Pages: 216
  • Format:
  • Pub. Date: Upcoming
  • Share:

The Europe cancer biomarkers market size is projected to register a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to rising attempts to create medicines that target new cancer biomarkers, as well as the launch of technologically improved companion diagnostic kits.

Europe Cancer Biomarkers Market

Cancer biomarkers are biological chemicals generated in response to cancer by tumor cells or human tissues, which are subsequently tested and assessed as indicators of malignant activities in the body. Cancer biomarkers are widely utilized in the diagnosis and treatment of cancer patients. Biomarkers are used in the follow-up surveillance and early identification of probable recurring illness in cancer patients who have had curative surgery. DNA, RNA, microRNAs, and proteins are all used to make molecular changes that are used to diagnose cancer. To lessen the emotional and physical effect of cancer on patients and their families, governments in many nations are focused on investing in cancer prevention and early intervention.

Market Trends, Drivers, Restraints, and Opportunities

  • Rising awareness about customized medicine are projected to fuel the market during the forecast period.
  • Increasing attempts to create medicines that target new cancer biomarkers is key factor propelling the market.
  • High price of drug development is estimated to hinder the market growth.
  • Risk of failure associated with cancer treatment, and uncontrolled government laws act as major challenge that can impede the market expansion in the coming years.
  • R&D investment and technological advancement is expected to create lucrative opportunities for the market players.

Scope of the Report

The report on the Europe cancer biomarkers market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Europe Cancer Biomarkers Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Disease (Prostate Cancer, Breast Cancer, Lung Cancer, Colorectal Cancer, Cervical Cancer, and Others), Type (Protein Biomarkers, Genetic Biomarkers, and Others), Profiling Technology (OMICS Technology, Immunoassays, and Cytogenetics)

Geographical Scope

Europe

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Biomerieux; Thermo Fisher Scientific; F. Hoffmann-La Roche Ltd; Illumina Inc; Abbott Laboratories Inc

Market Segment Insights

The lung cancer segment is projected to hold a major market share

On the basis of disease, the Europe cancer biomarkers market is divided into prostate cancer, breast cancer, lung cancer, colorectal cancer, cervical cancer, and others. The lung cancer segment is expected to represent a key share of the market during the forecast period. Lung cancer is caused by the uncontrolled proliferation of abnormal cells in one or both lungs. Persons who smoke have the maximum risk of lung cancer, despite the fact that it can harm people who have never smoked. Other risk factors include secondhand smoking, asbestos, some metals, certain organic compounds, radiation, air pollution, and diesel exhaust at the workplace or in the environment. With the rise in cancer cases, millions of individuals throughout the world are becoming infected with COVID-19. Since the focus of healthcare facilities has switched to COVID-19, cancer patients' treatment has been restricted for a length of time, and cancer biomarker-related clinical studies have been suspended for a shorter amount of time, resulting in a little negative impact on the total market. As a result of the growing number of cancer cases, the European cancer biomarkers market is anticipated to develop significantly over the forecast period.

Europe Cancer Biomarkers Market

The genetic biomarkers segment is expected to grow at a rapid pace

Based on type, the Europe cancer biomarkers market is segregated into protein biomarkers, genetic biomarkers, and others. The genetic biomarkers segment is expected to represent a key share of the market during the forecast period. The primary technologies utilized for genetic biomarker identification and diagnosis include next-generation sequencing (NGS), gene expression profiling (microarray), and polymerase chain reaction (PCR). The market for genetic biomarkers is being driven by advances in high-throughput technology.

Europe Cancer Biomarkers Market

The OMICS segment is anticipated to register rapid CAGR

In terms of profiling technology, the Europe cancer biomarkers market is segmented into OMICS technology, immunoassays, and cytogenetics. The OMICS segment is expected to represent a key share of the market during the forecast period. The OMIC technologies and imaging technologies segment account for 79.5 % of the total market share and are expected to expand at a high CAGR. Furthermore, need for safe and cost-effective cancer medicines, advances in profiling technology, an increase in healthcare spending, lower genome sequencing costs, and demand for better cancer diagnostics and therapeutic procedures are expected to drive the market.

Europe Cancer Biomarkers Market

Segments

Segments Covered in the Report

The Europe cancer biomarkers market has been segmented on the basis of

Disease

  • Prostate Cancer
  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Cervical Cancer
  • Others

Type

  • Protein Biomarkers
  • Genetic Biomarkers
  • Others

Profiling Technology

  • OMICS Technology
  • Immunoassays
  • Cytogenetics

Key Players

  • Biomerieux
  • Thermo Fisher Scientific
  • F. Hoffmann-La Roche Ltd
  • Illumina Inc
  • Abbott Laboratories Inc

Competitive Landscape

Key players competing in the Europe cancer biomarkers market include Biomerieux, Thermo Fisher Scientific, F. Hoffmann-La Roche Ltd, Illumina Inc, and Abbott Laboratories Inc.

Some of these players are using several market strategies such as mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to increase their market shares.

Europe Cancer Biomarkers Market

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Cancer Biomarkers Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Cancer Biomarkers Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Cancer Biomarkers Market - Supply Chain
  4.5. Global Cancer Biomarkers Market Forecast
     4.5.1. Cancer Biomarkers Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Cancer Biomarkers Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Cancer Biomarkers Market Absolute $ Opportunity
5. Global Cancer Biomarkers Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Cancer Biomarkers Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Cancer Biomarkers Demand Share Forecast, 2019-2026
6. North America Cancer Biomarkers Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Cancer Biomarkers Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Cancer Biomarkers Demand Share Forecast, 2019-2026
7. Latin America Cancer Biomarkers Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Cancer Biomarkers Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Cancer Biomarkers Demand Share Forecast, 2019-2026
8. Europe Cancer Biomarkers Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Cancer Biomarkers Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Cancer Biomarkers Demand Share Forecast, 2019-2026
9. Asia Pacific Cancer Biomarkers Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Cancer Biomarkers Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Cancer Biomarkers Demand Share Forecast, 2019-2026
10. Middle East & Africa Cancer Biomarkers Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Cancer Biomarkers Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Cancer Biomarkers Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Cancer Biomarkers Market: Market Share Analysis
  11.2. Cancer Biomarkers Distributors and Customers
  11.3. Cancer Biomarkers Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. Biomerieux Thermo Fisher Scientific F. Hoffmann-La Roche Ltd Illumina Inc Abbott Laboratories Inc

Segments Covered in the Report

The Europe cancer biomarkers market has been segmented on the basis of

Disease

  • Prostate Cancer
  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Cervical Cancer
  • Others

Type

  • Protein Biomarkers
  • Genetic Biomarkers
  • Others

Profiling Technology

  • OMICS Technology
  • Immunoassays
  • Cytogenetics

Key Players

  • Biomerieux
  • Thermo Fisher Scientific
  • F. Hoffmann-La Roche Ltd
  • Illumina Inc
  • Abbott Laboratories Inc

Key players competing in the Europe cancer biomarkers market include Biomerieux, Thermo Fisher Scientific, F. Hoffmann-La Roche Ltd, Illumina Inc, and Abbott Laboratories Inc.

Some of these players are using several market strategies such as mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to increase their market shares.

Europe Cancer Biomarkers Market

Buy Report